USPTO serial 78707831
TARGETED IMMUNE THERAPY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHOSID, ROBIN S
- Law office
- TMEG LAW OFFICE 102 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with TARGETED IMMUNE THERAPY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, MA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joseph C. Zucchero
JOSEPH C ZUCCHERO KEOWN & ASSOCIATES500 W CUMMINGS PARK STE 1200WOBURN, MA 01801-6500UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Immunological products, biological, chemical and therapeutic preparations, chemical products, namely, synthetic oligonucleotides for use in the manufacture of pharmaceuticals for modulating the immune system, scientific research and development to enhance or induce the immune system response | ACTIVE | — |
| 005 | medical diagnostic and therapeutic preparations, namely, biologically active modulators, including, immune modulators and antisense DNA or RNA compounds, chemical modulators of gene expression working at DNA transcription, RNA or translation processes; immunomodulatory oligonucleotides namely, ingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; pharmaceuticals for use in the treatment of viral and bacterial infection, inflammatory disorders and diseases, asthma or allergies, cancer, and auto immune diseases and disorders and vaccine adjuvants to modulate the immune system; biologically active compounds for use in the treatment of viral and bacterial infection or diseases associated with cellular gene expressions by preventing the production of disease associated proteins made by said infectious agents or cellular genes | INACTIVE - INSUFFICIENT FEE RECEIVED | — |
| 042 | medical and scientific services namely provision of care in the field of immunology; medical and scientific research in the area of oligonucleotides or chemical products; research and development of pharmaceuticals and research products for others; biological and/or chemical research namely in the field of immunology | INACTIVE - INSUFFICIENT FEE RECEIVED | — |
| 044 | medical services, namely, providing medical care in the field of immunology | INACTIVE - INSUFFICIENT FEE RECEIVED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Idera
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TARGETED IMMUNE THERAPY
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 17, 2006 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 17, 2006 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 21, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 14, 2005 | NWAP | NEW APPLICATION ENTERED | — |